Metal Nanoparticles for Cancer Therapy, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (20 April 2024) | Viewed by 1097

Special Issue Editors


E-Mail Website
Guest Editor
Department of Applied Chemistry, National Institute of Technology (KIT), Gumi, Gyeongbuk 39177, Republic of Korea
Interests: NIR-absorbing nanomaterials; cancer therapy; microbial infections; multimodel imaging
Special Issues, Collections and Topics in MDPI journals

E-Mail Website1 Website2
Guest Editor
Department of Applied Chemistry, National Institute of Technology (KIT), Gumi, Gyeongbuk 39177, Republic of Korea
Interests: NIR-based nanoparticles; cancer therapy; phototherapy; chemodynamic therapy; multimodel imaging
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer remains a major threat to human health worldwide due to the intense physical pain, toxic side effects, and poor therapeutic effects associated with traditional therapeutic methods such as surgery and radiotherapy. Numerous studies have attempted to explore new therapeutic methods, such as chemotherapy (CHT), photothermal therapy (PTT), photodynamic therapy (PDT), chemodynamic therapy (CDT), sonodynamic therapy (SDT), immunotherapy (IMT), and starvation therapy (ST) with high efficiency and minimize side effects. Developing new multifunctional metal-based nanoparticles for cancer therapy has attracted tremendous attention in recent years because of the various advantages of the reduced rate of recurrent tumors and minimized side effects. In addition, a variety of metal-based nanomaterials with diagnostic imaging properties have been widely used to improve the imaging quality, leading to more efficient and promising applications in diagnostic imaging. Additionally, combination cancer therapy allows precise diagnosis and highly efficient tumor therapy.

We invite all researchers to submit their findings related to metal-based nanomaterials for various cancer treatments.

The Special Issue, entitled “Metal Nanoparticles for cancer therapy, Second Edition”, aims to collect as many original researchers and reviews concerning the synthesis of various metal-based nanomaterials, characterization, in vitro and in vivo cancer studies, and clinical trials in pharmaceutical fields as possible. In addition, work aiming to increase knowledge about the synthesis of various metal-based nanomaterials, characterization, and cancer treatments are welcome.

We look forward to receiving your contributions.

Prof. Dr. Panchanathan Manivasagan
Prof. Dr. Eue-Soon Jang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • various metal-based nanoparticles
  • green synthesis of nanoparticles
  • cancer therapy
  • synthesis and characterization
  • in vitro and in vivo studies
  • multimodel imaging
  • theranostics
  • tumor targeting
  • drug delivery system
  • phototherapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 9678 KiB  
Article
Triphenylphosphonium-Functionalized Gold Nanorod/Zinc Oxide Core–Shell Nanocomposites for Mitochondrial-Targeted Phototherapy
by Ara Joe, Hyo-Won Han, Yu-Ra Lim, Panchanathan Manivasagan and Eue-Soon Jang
Pharmaceutics 2024, 16(2), 284; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics16020284 - 16 Feb 2024
Viewed by 816
Abstract
Phototherapies, such as photothermal therapy (PTT) and photodynamic therapy (PDT), combined with novel all-in-one light-responsive nanocomposites have recently emerged as new therapeutic modalities for the treatment of cancer. Herein, we developed novel all-in-one triphenylphosphonium-functionalized gold nanorod/zinc oxide core–shell nanocomposites (CTPP-GNR@ZnO) for mitochondrial-targeted PTT/PDT [...] Read more.
Phototherapies, such as photothermal therapy (PTT) and photodynamic therapy (PDT), combined with novel all-in-one light-responsive nanocomposites have recently emerged as new therapeutic modalities for the treatment of cancer. Herein, we developed novel all-in-one triphenylphosphonium-functionalized gold nanorod/zinc oxide core–shell nanocomposites (CTPP-GNR@ZnO) for mitochondrial-targeted PTT/PDT owing to their good biocompatibility, tunable and high optical absorption, photothermal conversion efficiency, highest reactive oxygen species (ROS) generation, and high mitochondrial-targeting capability. Under laser irradiation of 780 nm, the CTPP-GNR@ZnO core–shell nanocomposites effectively produced heat in addition to generating ROS to induce cell death, implying a synergistic effect of mild PTT and PDT in combating cancer. Notably, the in vitro PTT/PDT effect of CTPP-GNR@ZnO core–shell nanocomposites exhibited effective cell ablation (95%) and induced significant intracellular ROS after the 780 nm laser irradiation for 50 min, indicating that CTPP in CTPP-GNR@ZnO core–shell nanocomposites can specifically target the mitochondria of CT-26 cells, as well as generate heat and ROS to completely kill cancer cells. Overall, this light-responsive nanocomposite-based phototherapy provides a new approach for cancer synergistic therapy. Full article
(This article belongs to the Special Issue Metal Nanoparticles for Cancer Therapy, 2nd Edition)
Show Figures

Figure 1

Back to TopTop